Andere Sprachen Jiangsu Yahong Meditech Co., Ltd.

Aktien

688176

CNE100005XW0

688176

Schlusskurs Shanghai S.E. Andere Börsenplätze 00:00:00 24.06.2024			% 5 Tage	% 1. Jan.
5,22 ^CNY	-5,78 %		-4,92 %	-51,58 %

17.06.	ReviR Therapeutics erreicht Meilenstein in der Entwicklung einer neuartigen Splicing-Therapie in Zusammenarbeit mit Asieris Pharmaceuticals	CI
12.05.	Photocure ASA Partner Asieris Pharmaceuticals gibt die Annahme des neuen Arzneimittelantrags für die behördliche Prüfung von Cevira in China bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

ReviR Therapeutics Reaches Milestone in Novel Splicing Therapy Development in Collaboration with Asieris Pharmaceuticals	17.06.
Photocure ASA Partner Asieris Pharmaceuticals Announces New Drug Application Acceptance for Regulatory Review of Cevira in China	12.05.
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
Tranche Update on Jiangsu Yahong Meditech Co., Ltd.'s Equity Buyback Plan announced on February 7, 2024.	02.04.
Asieris Pharmaceuticals Announces Release of Positive Results from Multicenter Phase III Global Clinical Study	19.03.
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	23.02.
Asieris Pharmaceuticals to Unveil First-Ever Results of the International Multicenter Phase III Clinical Study for 1702, a Non-Surgical Treatment for Cervical HSIL, at the 2024 EUROGIN	22.02.
Jiangsu Yahong Meditech to Buy Back Shares for Up to 100 Million Yuan	12.02.
Jiangsu Yahong Meditech Co., Ltd. announces an Equity Buyback for CNY 100 million worth of its shares.	07.02.
Jiangsu Yahong Meditech Co., Ltd. authorizes a Buyback Plan.	06.02.
Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, A Bladder Cancer Diagnosis and Management Drug, At the 2024 ASCO-GU	29.01.
Asieris Pharmaceuticals Announces Set-Up of the Women's Health Business Unit for Commercialization	09.01.
Asieris Pharmaceuticals Appoints Sophia Cao as Senior Vice President and Head of the Women's Health Business Unit	09.01.
Certain A Shares of Jiangsu Yahong Meditech Co., Ltd. are subject to a Lock-Up Agreement Ending on 7-JAN-2024.	07.01.
Jiangsu Yahong Meditech Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	30.10.23
Asieris Pharmaceuticals Unveils Results of Its Hexvix[®] (Apl-1706) Phase III Clinical Trial in China	12.10.23
Photocure Partner Asieris Pharmaceuticals to Present First Results for its Hexvix Phase III Clinical Trial in China at the SIU2023 Annual Meeting	07.10.23
Jiangsu Yahong Meditech Completes Phase III Trial Into APL1702 Drug; Shares Drop 4%	21.09.23
Asieris Pharmaceuticals Announces the First Non-Vaccine Investigational Product for Cervical HSIL Has Achieved Its Primary Endpoint	20.09.23
Jiangsu Yahong Meditech Co., Ltd.(XSSC:688176) added to S&P Global BMI Index	18.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Jiangsu Yahong Meditech Co., Ltd.

Aktien

688176

CNE100005XW0

688176

Andere Sprachen

Filter